Regeneron Pharmaceuticals Inc. (REGN): Price and Financial Metrics
GET POWR RATINGS... FREE!
REGN POWR Grades
- REGN scores best on the Quality dimension, with a Quality rank ahead of 92.12% of US stocks.
- REGN's strongest trending metric is Growth; it's been moving down over the last 177 days.
- REGN's current lowest rank is in the Growth metric (where it is better than 4.49% of US stocks).
REGN Stock Summary
- With a market capitalization of $74,790,609,724, REGENERON PHARMACEUTICALS INC has a greater market value than 97.57% of US stocks.
- REGN's went public 31.51 years ago, making it older than 85.02% of listed US stocks we're tracking.
- The volatility of REGENERON PHARMACEUTICALS INC's share price is greater than that of just 13.31% US stocks with at least 200 days of trading history.
- If you're looking for stocks that are quantitatively similar to REGENERON PHARMACEUTICALS INC, a group of peers worth examining would be AMAT, LRCX, SNPS, CDNS, and VRTX.
- REGN's SEC filings can be seen here. And to visit REGENERON PHARMACEUTICALS INC's official web site, go to www.regeneron.com.
REGN Valuation Summary
- REGN's price/sales ratio is 5.3; this is 178.95% higher than that of the median Healthcare stock.
- REGN's EV/EBIT ratio has moved up 19.4 over the prior 243 months.
Below are key valuation metrics over time for REGN.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| REGN | 2022-09-23 | 5.3 | 3.7 | 13.4 | 11.8 |
| REGN | 2022-09-22 | 5.3 | 3.6 | 13.2 | 11.6 |
| REGN | 2022-09-21 | 5.2 | 3.6 | 13.1 | 11.6 |
| REGN | 2022-09-20 | 5.4 | 3.7 | 13.5 | 11.9 |
| REGN | 2022-09-19 | 5.5 | 3.8 | 13.7 | 12.1 |
| REGN | 2022-09-16 | 5.4 | 3.7 | 13.6 | 12.0 |
REGN Growth Metrics
- The 3 year cash and equivalents growth rate now stands at 95.83%.
- Its 4 year revenue growth rate is now at 68.65%.
- The 2 year cash and equivalents growth rate now stands at 51.51%.
The table below shows REGN's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-06-30 | 14,226.8 | 8,452.2 | 5,686.8 |
| 2022-03-31 | 16,508.1 | 8,514.5 | 7,933.6 |
| 2021-12-31 | 16,071.7 | 7,081.3 | 8,075.3 |
| 2021-09-30 | 13,542.9 | 5,939.8 | 6,995.5 |
| 2021-06-30 | 12,384.1 | 2,271.9 | 6,205.4 |
| 2021-03-31 | 9,197.6 | 2,588.6 | 4,003.8 |
REGN's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- REGN has a Quality Grade of B, ranking ahead of 86.94% of graded US stocks.
- REGN's asset turnover comes in at 0.683 -- ranking 43rd of 681 Pharmaceutical Products stocks.
- JAZZ, AGLE, and VERU are the stocks whose asset turnover ratios are most correlated with REGN.
The table below shows REGN's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.683 | 0.868 | 0.456 |
| 2021-03-31 | 0.562 | 0.868 | 0.315 |
| 2020-12-31 | 0.536 | 0.868 | 0.292 |
| 2020-09-30 | 0.540 | 0.880 | 0.283 |
| 2020-06-30 | 0.543 | 0.882 | 0.282 |
| 2020-03-31 | 0.553 | 0.897 | 0.221 |
REGN Price Target
For more insight on analysts targets of REGN, see our REGN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $683.25 | Average Broker Recommendation | 1.52 (Moderate Buy) |
REGN Stock Price Chart Interactive Chart >
REGN Price/Volume Stats
| Current price | $728.18 | 52-week high | $754.67 |
| Prev. close | $688.87 | 52-week low | $538.01 |
| Day low | $694.64 | Volume | 548,773 |
| Day high | $734.55 | Avg. volume | 708,093 |
| 50-day MA | $640.18 | Dividend yield | N/A |
| 200-day MA | $637.19 | Market Cap | 79.38B |
Regeneron Pharmaceuticals Inc. (REGN) Company Bio
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors. (Wikipedia:Source)
Latest REGN News From Around the Web
Below are the latest news stories about REGENERON PHARMACEUTICALS INC that investors may wish to consider to help them evaluate REGN as an investment opportunity.
Possible bearish signals as Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) insiders disposed of US$16m worth of stockOver the past year, many Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) insiders sold a significant stake in the... |
Aflibercept 8 mg Positive Pivotal Results in Diabetic Macular Edema and Wet Age-Related Macular Degeneration Presented at AAORegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the first presentations of positive detailed results from two pivotal trials investigating novel aflibercept 8 mg with 12- and 16-week dosing regimens, compared to EYLEA® (aflibercept) Injection, in patients with diabetic macular edema (DME) and wet age-related macular degeneration (wAMD). The data were presented in a late-breaking session at the American Academy of Ophthalmology (AAO) annual meeting in Chicago and will support the s |
Illumina Aims to Push Genetics Beyond the Lab With $200 Genome(Bloomberg) -- Illumina Inc. says it can read a person’s entire genetic code for as little as $200 with its new sequencing machine, bringing the company within reach of its long-promised goal of the $100 genome.Most Read from BloombergMacKenzie Scott Files for Divorce From Science Teacher HusbandMeta to Cut Headcount for First Time, Slash Budgets Across TeamsStocks Plummet to 22-Month Low as Fed Hawks Circle: Markets WrapTrump Refuses to Delay Florida Deposition in Phone-Fraud Case Despite Hurri |
Biotech Stock Roundup: BIIB's AD Drug Data & REGN, IONS, VRTX's UpdatesRegulatory and pipeline updates from BIIB and IONS are the key highlights from the biotech sector during the past week. |
Sanofi's (SNY) Dupixent Gets FDA Nod for Prurigo NodularisThe FDA approves Sanofi (SNY) and its partner Regeneron's Dupixent (dupilumab) for the treatment of adult patients with prurigo nodularis. |
REGN Price Returns
| 1-mo | 25.41% |
| 3-mo | 22.06% |
| 6-mo | 2.80% |
| 1-year | 27.57% |
| 3-year | 157.37% |
| 5-year | 59.67% |
| YTD | 15.31% |
| 2021 | 30.72% |
| 2020 | 28.66% |
| 2019 | 0.53% |
| 2018 | -0.65% |
| 2017 | 2.42% |
Continue Researching REGN
Want to see what other sources are saying about Regeneron Pharmaceuticals Inc's financials and stock price? Try the links below:Regeneron Pharmaceuticals Inc (REGN) Stock Price | Nasdaq
Regeneron Pharmaceuticals Inc (REGN) Stock Quote, History and News - Yahoo Finance
Regeneron Pharmaceuticals Inc (REGN) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...